Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007 Jun;137(5):461-7 PMID: 17459051

Pubmed ID



The discovery and approval of imatinib drastically changed the therapeutic algorithm for chronic myeloid leukaemia (CML). Imatinib is now considered the therapy of choice for patients with newly diagnosed CML, including those previously considered candidates for allogeneic haematopoietic cell transplantation (HCT). We compared numbers and types of allogeneic HCTs performed for CML in North America before and after the introduction of imatinib, and publication of the International Randomized Trial of Interferon and STI571 (IRIS) using transplants reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The number of HCTs for CML registered with the CIBMTR in 1998 was 617; 62% were performed in first chronic phase (CP1). Only 1% of patients had received imatinib prior to transplantation. In 2003, the number of HCTs reported was 223; 44% were performed in CP1 and 77% of patients received imatinib prior to transplantation. The introduction of imatinib therapy has had a profound impact on the use of allogeneic transplantation for CML, with a marked decrease in the number of transplants for CML and an accompanying decrease in the proportion done in CP1. Most patients now receive a trial of imatinib before proceeding to HCT.

Author List

Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL, Sobocinski KA, Horowitz MM, Chronic Leukemia Working Committee, Center for International Blood and Marrow Transplant Research


Mary M. Horowitz MD, MS Center Director, Professor in the Medicine department at Medical College of Wisconsin


2-s2.0-34247863611   63 Citations

MESH terms used to index this publication - Major topics in bold

Antineoplastic Agents
Clinical Protocols
Databases, Factual
Disease Progression
Hematopoietic Stem Cell Transplantation
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Patient Selection
Transplantation, Homologous
United States
jenkins-FCD Prod-296 4db9d02597e0a2e889e230f853b641c12f1c3ee3